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Abstract:  
AIM: To assess whether the proportion of patients aged 70 and over with ER+ operable breast 
cancer in England who are treated with surgery has changed since 2002, and to determine 
whether age and individual level factors including tumour characteristics and co-morbidity 
influence treatment choice. 
METHODS: A retrospective cohort analysis of routinely collected cancer registration data from 
two English regions (West Midlands, Northern & Yorkshire) was carried out (n = 17,129). Trends 
in surgical use over time for different age groups were assessed graphically and with linear 
regression. Uni- and multivariable logistic regressions were used to assess the effects of age, 
comorbidity, deprivation and disease characteristics on treatment choice. Missing data was 
handled using multiple imputation. 
RESULTS: There is no evidence of a change in the proportion of patients treated surgically over 
time. The multivariable model shows that age remains an important predictor of whether or not 
a woman with ER+ operable breast cancer receives surgery after covariate adjustment (Odds 
ratio of surgery vs no surgery, 0.82 (per year over 70)). Co-morbidity, deprivation, symptomatic 
presentation, later stage at diagnosis and low grade are also associated with increased 
probability of non-surgical treatment. 
CONCLUSION: Contrary to current NICE guidance in England, age appears to be an important 
factor in the decision to treat operable ER+ breast cancer non-surgically. Further research is 
needed to assess the role of other age-related factors on treatment choice, and the effect that 
current practice has on survival and mortality from breast cancer for older women. 
Keywords: Breast cancer, elderly, surgery, , comorbidity, retrospective study 
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Introduction 
More than 16,000 women aged 70 or over are diagnosed with breast cancer in the UK each year, 
accounting for more than 30% of all diagnoses (1). The number  of women affected  will increase 
over time due to the ageing population (2).  Most older women are diagnosed with oestrogen 
receptor positive disease (ER+), with estimates ranging from 80-90% (3,4). For postmenopausal 
women with operable ER+ breast cancer, NICE recommends that usual treatment should consist 
of surgery with adjuvant endocrine therapy using an aromatase inhibitor, or surgery only if 
recurrence risk is very low. However, ER+ tumours can respond well to primary endocrine 
therapy (PET), which consists of sole use of anti-oestrogen therapy without surgery. 
The most recent NICE guidelines , issued in 2009, state that PET should only be offered to 
patients if “significant comorbidity precludes surgery” (page 86), and that age should not affect 
the decision by itself (5).  For patients aged over 70, non-surgical treatment is used in up to 40% 
of patients, compared with less than 6% in women under 70 (6). There is considerable regional 
variation in rates of non-surgical treatment within the UK, which is unlikely to be explained solely 
by population differences or administrative error.  
The reason for such high rates of PET usage in older women in unclear.  Mortality from breast 
surgery is very rare in all age groups (7), and where there are concerns over fitness it is often 
possible to resect the primary tumour under local anaesthetic. In other developed nations such 
as the USA, Australia, Japan and the Netherlands rates of surgical treatment of breast cancer are 
higher than in the UK (8) ; for example in the US over 90% of women aged 90 years and over 
with stage I or II disease are treated surgically (9).  As a result it is unlikely that observed rates of 
non-surgical treatment in the UK are the result of all such patients being too unfit to tolerate 
surgery. 
Historical evidence in support of PET compared with surgical management is derived from 
several trials run over 20 years ago, which showed no survival advantage for surgery in women 
over the age of 70 (10). However, in all trials local disease control was observed to be much 
worse for patients treated with PET compared with surgery, regardless of whether adjuvant 
endocrine therapy was used. Poor local disease control can result in increased risk of a change in 
management as well as physical and/or psychological morbidity. None of these trials factored 
comorbidity or frailty into the analysis, and patients were fit for surgery under general 
anaesthetic. A recent study has reviewed data from UK cohort studies, which are more likely to 
reflect actual clinical practice. These studies  have shown that surgery may be advantageous for 
both overall and breast-cancer specific survival (11).  The limitations of cohort studies must be 
recognised. There will be characteristics related to both treatment choice and survival which 
differ between groups (e.g. frailty, functional status) and this will inevitably lead to higher rates 
of other cause mortality in the non-surgically treated group. However rates of breast cancer 
specific survival should be less affected, and these do show some benefit for surgery.  A corollary 
to this is that the high levels of PET use in women aged 70 and over in England  may partly 
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explain why relative survival for older women with  breast cancer is poor when compared to 
their contemporaries in other developed nations (12). 
Our study aims to analyse UK practice using retrospective cohort study in older women with 
operable, ER positive breast cancer in order to establish which factors determine selection for 
surgery or primary endocrine therapy.  
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Methods 
Data on all first diagnoses of invasive breast cancer in women aged 70 and over between the 
years of 2002 and 2010 were acquired for two UK cancer registry regions (West Midlands, 
Northern & Yorkshire). Variables provided for analysis are shown in Table 1. Comorbidity was 
derived from linked records in the Hospital Episode Statistics dataset and aggregated using the 
Charlson Co-morbidity Index (13) by counting diagnostic codes recorded in episodes in the 18 
months prior to diagnosis,  an approach used in other studies using routine registration data 
(14). Deprivation was recorded as quintile of the income domain of the English Indices of 
Multiple Deprivation 2010 (15), derived from the patient’s postcode based on the proportion of 
households in the local area in receipt of various forms of financial assistance from the state. 
Analyses are restricted to the subgroup of patients with operable ER+ disease at diagnosis. 
Patients with metastatic disease at diagnosis were excluded. It was not possible to identify 
locally advanced disease definitively due to incomplete staging data, so this criterion may 
include a small number of tumours which were initially inoperable.  
Oestrogen receptor (ER) status is not completely recorded, and in particular was only collected 
routinely by the Northern & Yorkshire registry from 2009. However, it is known that the 
completeness of recording of hormone therapy use for these patients was good (6).  As a proxy, 
it was assumed that any patient with unknown ER status but a record of hormone therapy had 
ER+ disease, as hormone therapy is only effective in these patients. Patients with unknown ER 
status and no record of hormone therapy were excluded from further analysis. Patients known 
to have died within 3 months of diagnosis were also excluded, as these patients are likely to have 
died before planned treatments could commence or will have already had stage 4 disease at the 
time of diagnosis. 
Primary treatment was dichotomised as “surgery” or “no surgery” according to whether the 
patient had an episode of breast surgery recorded within 6 months of diagnosis (using OPCS4 
codesThe proportion of patients treated surgically for each year at diagnosis was plotted for the 
age subgroups 70-79, 80-89 and 90+. Linear regression using year of diagnosis as the 
independent variable and controlling for age subgroup was used to investigate evidence of 
temporal trends in treatment. Graphical methods were used to display the associations between 
age, deprivation and treatment. Simple logistic regression was used to identify associations 
between covariates with complete data and treatment choice.  The joint effect of selected 
patient level factors (age, deprivation, comorbidity, method of detection,  tumour diameter, 
nodal status, tumour grade) on the probability of surgical treatment was assessed using 
multivariable logistic regression.  
Some covariates contain missing values. The “gold standard” for tumour characteristics and 
staging data is to derive them from pathology reports, but such information will be incomplete if 
surgery is omitted and may sometimes be missing for surgically treated patients as well. 
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Although values may be recorded on the basis of other information (biopsy, imaging, etc.), in 
some cases no value is available. Analyses based on case-wise deletion of individuals with 
missing values can lead to biased results due to selection bias if data is not missing completely at 
random, and also results in a loss of statistical precision. Missing data on disease characteristics 
and comorbidity was handled as suggested by Nur et al (16), using the method of multiple 
imputation by chained equations (MICE) (17).  This method involves imputing missing values 
multiple times, conditional on the other values observed in the dataset. Twenty-five completed 
datasets were used for the multivariable analyses only. As the imputation method draws on 
information from many  covariates, this method was not used to estimate associations between 
individual variables with incomplete data and treatment choice; doing so can result in incorrect 
estimates for standard errors (18) .Results from the 25 multivariable regression models fitted to 
each of the imputed datasets were combined using methods described by Rubin (19). Covariates 
with over 50% missing data were not included in the base-case regression models. Numeric 
stage was included in the imputations but omitted from the regressions in favour of tumour size 
and nodal status. This decision was taken because numeric stage is closely correlated with these 
variables by definition, and so including it would make identification of the effect of tumour size 
and node positivity difficult.  
The ability of the regression model to predict whether a patient would be treated surgically was 
assessed by calculating the ROC curve and its corresponding area under the curve (AUC) statistic 
(20). All analyses were conducted using the open source statistical programming language R 
(version 3.0.1) (21). The user-contributed CRAN packages “mi” (22)and “pROC” (23) were used 
to implement the MICE algorithm and the ROC analyses respectively. 
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Results 
The dataset contained records on 23,960 diagnoses of primary breast cancer. After applying the 
exclusion criteria described in the previous section, a total of 17,129 records remained for analy-
sis (Fig 1). On the basis of the assumptions made to define ER status, it was estimated that 77% 
of this group had ER+ tumours. This is in line with audit data for England which shows that be-
tween 78 and 80% of women in this age group present with ER+ disease.  
Patient characteristics are shown in Table 1. Missing data is more prevalent in patients who are 
treated non-surgically. In particular, information on nodal status is only recorded for 9% of pa-
tients treated non-surgically compared with 84% of patients treated surgically. This finding has 
been noted in previous audits of cancer registration data, and is unsurprising since tumour size 
and nodal status is most accurately assessed from post-operative pathology based on the re-
sected tumour and lymph nodes. Regardless of treatment, the rates of missing data for most 
incomplete covariates increase with age. 
There was no evidence of a trend in the proportion of patients receiving surgical treatment 
between 2002 and 2010 regardless of age at diagnosis (Fig 2). The modelled increase in the 
proportion surgically treated per year was 0.00 for age 70-79 (p = 0.39), 0.00 for age 80-89 (p = 
0.33) and 0.00 for age 90+. As a sensitivity analysis the proportions were also calculated for the 
whole dataset regardless of stage at diagnosis and ER status, but again no trends were observed 
(data not shown). 
The univariable regressions show that increased age at diagnosis, high deprivation and 
symptomatic presentation are all strongly associated with non-surgical treatment, without 
accounting for the effects of other variables (Table 2).  The negative association between the 
probability of surgical treatment and age at diagnosis can be seen in Figure 3. The proportion 
receiving surgery declines from 91.1% at age 70 to 38.5% at age 85 and less than 3% at age 95 
and over. Between the ages of 70 and 85 deprivation is associated  with non-surgical treatment. 
The observed proportion of surgical treatment is greater in the least deprived quintile compared 
with the most deprived quintile at all ages in this range, with the absolute increase associated 
with low deprivation ranging from  between 4% (at age 79) and 25% (at age 78).For women aged 
over 85, no association with deprivation is observed. Although presentation at screening is 
strongly associated with surgery,  screening was not routinely offered to this population (24) and 
these women are most likely self-referrals. 
The multivariable logistic regression model after combining results from the imputed datasets is 
shown in Table 3. HER2 status was not included due to the majority of data being missing. 
Exploratory analysis of the imputed datasets did not raise major concerns about the plausibility 
of the imputed values (data not shown), although by definition any discrepancies cannot be 
measured.  
All variables assessed in the final model are significantly associated with treatment type. Older 
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age, symptomatic presentation, increased Charlson score, high income deprivation, lymph node 
involvement, larger tumour size and grade 1 or 2 disease are associated with a higher probability 
of non-surgical treatment. The ROC curve for the logistic model is presented in Figure 4, as well 
as for a decision rule based on using age at diagnosis alone to predict treatment. The area under 
the model curve (AUC) is 0.848 (95% CI, 0.843 – 0.854), indicating that the model discriminates 
well between patients treated surgically and non-surgically. The regression model provides a 
modest improvement over using age as the sole predictor, which has AUC = 0.807 (95% CI, 0.801 
– 0.814). This shows that age at diagnosis accounts for much of the variability in treatment 
decision making in this population. 
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Discussion 
This analysis suggests that age is the single most important factor associated with non-surgical 
treatment of older breast cancer patients with operable ER+ disease in England. The finding 
persists when income deprivation, co-morbidities and disease characteristics are accounted for, 
although the multivariable model shows that these factors do predict treatment to a lesser 
extent. There is no evidence of a change in the rate of surgical treatment over time. The model 
discriminates well between patients treated surgically and non-surgically, but there is residual 
variability in treatment decisions not explained by this data. There is also a suggestion that 
socio-economic factors have an independent effect on treatment choice, with increased income 
deprivation being predictive of non-surgical treatment for patients aged 70-85. Overall, the 
results of this model suggest that NICE guidance for the use of PET is not being adhered to 
consistently. 
Our results are largely consistent with those of other UK cohort studies (25–28). In particular, in 
a previous analysis of cancer registration data on diagnoses between the years of 1997 and 
2005, Lavelle et al found that age remains a significant predictor of treatment after controlling 
for comorbidity (26). Our analysis builds on this previous work in a number of ways. Firstly, 
inclusion of diagnoses up to and including 2010 means that it is more reflective of contemporary 
practice. In recent years completeness of cancer registration data has improved, so the findings 
of this analysis should be less prone to missing data bias (6). Our study considers the joint impact 
of all variables by accounting for missing data using multiple imputation. This method is less 
prone to bias than other approaches to analysing registry data such as complete case analysis or 
treating “missing” as a category in a factor variable (16). There is, however, no perfect method 
for accounting for missing data and by definition results cannot be verified from the data alone. 
Our multivariable analysis demonstrates that age  is highly predictive of non-surgical treatment, 
and that comorbidity, deprivation and disease characteristics also contribute to this treatment 
decision. This conclusion from the analysis is possible despite this missing data, but if the 
relationship between disease characteristics and other factors differs significantly between the 
PET and surgery groups there will be some bias in estimates of the regression coefficients for 
these characteristics. 
Our data shows no evidence of any trend in the use of surgery in the West Midlands and 
Northern & Yorkshire regions between 2002-10. This contrasts with emerging evidence from the 
Netherlands which shows a marked decrease in the use of surgery in this population over the 
same period, though rates remain considerably higher than in the UK  (29). Interestingly, overall 
and relative survival at 5 years remained almost unchanged in the Netherlands over this time 
period. This suggests that non-surgical treatment can result in good outcomes, provided it is 
targeted effectively, though care must be taken when comparing data from different countries 
due to differences in demographics and health systems. 
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 Our methods have a number of limitations. It is known that the prevalence of chronic conditions 
increases with age, and older people are more likely to be diagnosed with multiple such 
conditions (multimorbidity) (30). The HES based method used to measure comorbidity may 
underestimate the true burden of comorbidity in the elderly.  This method has been adopted as 
standard in other analyses of cancer registration data (14,26), which have found that the 
resultant measure is positively correlated with negative outcomes. However, the proportion of 
patients recorded as having one or more comorbid condition in the dataset is considerably lower 
than estimates for US breast cancer patients (9) and in the general UK population (30) in this age 
range. This may be because some chronic conditions in the elderly are primarily controlled in a 
non-inpatient setting and are therefore not identified in in-patient and day case HES data. This 
also explains the higher rate of missing values within the “no surgery” arm. Future 
developments in health care data linkage may allow for more accurate identification of 
comorbidities using routine data sources, which in turn would allow for a more in depth 
understanding about the relationship this plays with choices about breast cancer therapy   In 
addition, it is not clear that the Charlson index is the most appropriate method of aggregating 
comorbidity in this study, as it was originally developed and validated as a prognostic index for 
mortality and is not elderly-specific (13).  
Multimorbidity alone does not fully describe age-related heterogeneity in health (31), and other 
measures such as functional status and cognitive function are known to be age dependent (32). 
These factors do not necessarily correlate with comorbidity in an elderly population (33) and are  
missing from our dataset. Poor functional status has been observed to be predictive of non-
surgical treatment in other prospective cohort studies (27). Omission of surgery may be  
reasonable given such patients may be more prone to adverse outcomes after surgery and be at 
greater risk of loss of independence due to frailty. However the potential effect on survival 
outcomes must not be ignored when making treatment decisions.  
The impact of patient choice on treatment decisions is not recorded in registry data. Patient 
choice may partly reflect the preference of the clinician (34). Qualitative research has shown that 
older breast cancer patients were largely passive in making treatment decisions and deferred 
choice to the staff responsible for their care (35). A recent study has shown that where patients 
perceive that their role in treatment decision making was not discussed, they were more likely to 
be treated non-surgically (27). Interestingly, the authors found that for 46% (123/267) of patients 
who felt this way, the responsible clinician believed that the patient took an active or 
collaborative role in choosing treatment. This suggests that high rates of PET are very unlikely to 
be solely due to patients actively opting out of surgery, and that there is scope for improving 
patient involvement in treatment decision making. 
In summary, this study has found that age remains animportant factor in the  use of non-surgical 
treatment in older women with ER+ operable breast cancer, even after adjusting for disease 
characteristics, co-morbidity and deprivation.  Although not all relevant factors can be assessed 
using cancer registration data, the resulting model discriminates well between patients treated 
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surgically and non-surgically. Further research is ongoing to assess the effect that treatment with 
PET has on survival, which in time will hopefully allow for more evidence based guidelines to be 
developed for this growing population. 
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Figure 2: Proportion of patients treated surgically over time, split by 10 year age bands 
for age at diagnosis 
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 Figure 3: Proportion of ER+ patients with early breast cancer treated with surgery by age at 
diagnosis, for the whole population (points) and within the top and bottom quintiles of 
deprivation. Bars and ribbons indicate 95% confidence intervals 
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Figure 4: Receiver-operator characteristic (ROC) curves for the predictions from the multivariable logistic regression 
model, and using age as a sole predictor 
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Table 1: Patient characteristics 
Patient and tumour 
characteristics 
 Prevalence (%) Number who 
underwent surgery 
Rate of surgical 
treatment 
  17129 9955 58.1% 
Age at diagnosis (years)     
 70-74 4576 (27) 3958 86.5% 
 75-79 4582 (27) 3349 73.1% 
 80-84 3960 (23) 1913 48.3% 
 85-89 2645 (15) 625 23.6% 
 90-94 1053 (6) 104 9.9% 
 95+ 313 (2) 6 1.9% 
 Mean 79.6 years 76.6 years  
Deprivation Quintile     
 1 (least deprived) 2785 (16) 1800 64.6% 
 2 3540 (21) 2178 61.5% 
 3 3390 (20) 2012 59.4% 
 4 3636 (21) 1977 54.4% 
 5 (most deprived) 3779 (22) 1989 52.6% 
Comorbidity (HES proxy 
Charlson) 
    
 0 12160 (71) 8719 71.7% 
 1 1253 (7) 588 46.9% 
 2 629 (4) 279 44.4% 
 >2 337 (2) 77 22.9% 
 Missing 2750 (16) 292 10.6% 
Method of detection     
 Symptomatic 16014 (93) 8888 55.5% 
 Screening 1115 (7) 1067 95.7% 
Tumour Size at Diagnosis 
(diameter, mm, invasive 
component) 
    
 (<10) 762 (4) 680 89.2% 
 (10-20) 3702 (22) 3154 85.2% 
 (20-50) 6465 (38) 4844 74.9% 
 (>50) 862 (5) 555 64.4% 
 Missing 5338 (31) 722 13.5% 
Nodal Status     
 Negative 5107 (30) 4847 94.9% 
 Positive 3881 (23) 3480 89.7% 
 Missing 8141 (47) 1628 20.0% 
TNM Stage     
 I 4215 (25) 3412 80.9% 
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 II 6617 (38) 5097 77.0% 
 III 1295 (7) 877 67.7% 
 Missing 5002 (29) 569 11.4% 
Bloom Richardson Grade     
 1 2720 (16) 1783 65.6% 
 2 8567 (50) 5516 64.4% 
 3 3200 (19) 2385 74.5% 
 Missing 2642 (15) 271 10.3% 
HER2 Status     
 Negative 3821 (22) 2824 73.9% 
 Positive 514 (3) 367 71.4% 
 Missing 12794 (75) 6764 52.9% 
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Table 2: Odds ratios of complete covariates on surgical treatment, calculated using uni-
variable logistic regression. Values < 1 indicate reduced probability of surgical 
treatment (* indicates p-value for trend) 
  
Odds Ratio 
(surgery vs 
no surgery) 
95% 
confidence 
interval P 
Age at diagnosis (per year over 70) 0.81 (0.80, 0.81) <0.001 
Deprivation Qunitile 1 (least) Reference - <0.001* 
 2 0.86 (0.79, 0.97)  
 3 0.80 (0.72, 0.89)  
 4 0.65 (0.59, 0.72)  
 5 (most) 0.61 (0.55, 0.67)  
Detection Route Screened Reference -  
 Symptomatic 0.056 0.042 <0.001 
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Table 3: Multivariable logistic regression of the probability of surgical treatment given individual 
level characteristics (* indicates p-value for trend) 
  
Odds Ratio (surgery 
vs. no surgery) 
Lower 95% 
limit P - value 
Age at diagnosis (per year over 70) 0.82 (0.81,  0.82) <0.001 
Charlson Index (per unit increase) 0.53 (0.50, 0.56) <0.001 
Deprivation 1 (least) Reference - <0.001* 
 2 0.88 (0.77, 1.00)  
 3 0.83 (0.73, 0.95)  
 4 0.69 (0.61, 0.78)  
 5 (most) 0.61 (0.54, 0.69)  
Detection Route Screened Reference - <0.001 
 Symptomatic 0.34 (0.25, 0.47)  
Bloom-Richardson Grade 1 Reference - <0.001* 
 2 1.10 (0.98, 1.23)  
 3 1.82 (1.58, 2.11)  
Nodal Status Negative Reference - 0.015 
 Positive 0.85 (0.74, 0.97)  
Tumour Size 
(per mm increase in 
diameter) 
0.982 (0.979, 0.985) <0.001 
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Original data (n = 23,960)
Flagged as stage IV or mets at 
diagnosis (n=1,511)
No distant metastases reported 
(n = 22,449)
Invasive BC (n = 22,338)
Flagged as non-invasive/Paget’s 
disease (n = 111)
ER+ or unknown (n = 20,858)
Flagged as ER- (n = 1,480)
ER+ or unknown with hormone 
therapy (n = 17,706)
ER unknown and no hormone 
therapy (n = 3,152)
Death < 92 days from diagnosis  
(n = 577)
Assumed operable ER+                
(n = 17,129)
